1999 Fiscal Year Final Research Report Summary
Can antisense for p53 increase the chemosensitivity of anticancer drugs for lung cancer?
Project/Area Number |
10671133
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
General surgery
|
Research Institution | Keio university |
Principal Investigator |
KAWAMURA Masafumi School of Medicine, Keio university Assistant professor, 医学部, 専任講師 (70169770)
|
Co-Investigator(Kenkyū-buntansha) |
GIKA Masatoshi School of Medicine, Keio university Instructor, 医学部, 助手 (60276269)
KUBOTA Tetsuro School of Medicine, Keio university Assistant professor, 医学部, 専任講師 (00118944)
|
Project Period (FY) |
1998 – 1999
|
Keywords | anticacer drug / chemosensitivity testing / p53 / antisense / cancer suppression gene |
Research Abstract |
Chemosensitivity testing of anticancer drugs for lung cancer was measured by use of collagen gel droplet embedded drug sensitivity test (CDDST). Corelation between CDDST and clinical response was as below. True positive ratio was 80%. True negative ratio was 100%. Accuracy was 83.3%. Chemosensitivity testings were successfully carried out in 77.2% of 149 resected tumor specimen, 34.1% of 44 bronchoscopic biopsied specimens, 73.6% of 72 disected or biopsied lymph nodes, and 56.4% of 39 aspirated pleural or pericardial effusion. Chemosensitivities of some anticancer drugs for some lung cancercell lines were increased at 42℃ incubation in CDDST.Apoptosis in lung cancer cell lines could be induced at 42℃ in CDDST, if incubation time was prolonged. During this process, increase of p53 m-RNA could not detected. In lung cancer cell line apoptosis might be initiated by activation of p53 protein itself and p53 m-RNA might not relate directly with the initiation of apoptosis. Actually the increase of chemosensitivity of anticancer drugs for lung cancer cell lines were not observed in CDDST with p53 antisense.
|
Research Products
(4 results)